Last reviewed · How we verify
Standard Palliative Chemotherapy
At a glance
| Generic name | Standard Palliative Chemotherapy |
|---|---|
| Sponsor | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Evidence-Based Nursing Plus Progressive Exercise for Cancer-Related Fatigue in Advanced Lung Cancer (NA)
- Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) (PHASE1, PHASE2)
- Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan (NA)
- Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT (PHASE1, PHASE2)
- Online Nutrition Education to Decrease the Side Effects of Chemotherapy in Patients With Breast Cancer (NA)
- A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort) (PHASE2)
- Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors (NA)
- G-CSF-Induced Bone Pain and Supportive Care Approaches
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: